Active Biotech inks global patent license agreement with Oncode Institute
11 Feb 2022 //
PHARMABIZ
Active Biotech: Year End Report 2021
09 Feb 2022 //
GLOBENEWSWIRE
Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
07 Feb 2022 //
GLOBENEWSWIRE
New preclinical data on tasquinimod will be presented at ASH
04 Nov 2021 //
GLOBENEWSWIRE
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating
02 Oct 2021 //
GLOBENEWSWIRE
Active Biotech announces first patient dosed in ph 1b/2a study of tasquinimod
03 Aug 2020 //
GLOBENEWSWIRE